Form 8-K - Current report:
SEC Accession No. 0001213900-24-097449
Filing Date
2024-11-13
Accepted
2024-11-13 16:05:08
Documents
14
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221098-8k_immu.htm   iXBRL 8-K 34776
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 13, 2024 ea022109801ex99-1_immucell.htm EX-99.1 103130
  Complete submission text file 0001213900-24-097449.txt   322046

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20241113.xsd EX-101.SCH 3015
4 XBRL LABEL FILE iccc-20241113_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20241113_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221098-8k_immu_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 241453972
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)